Literature DB >> 8591948

Enteric absorption of ciprofloxacin during the immediate postoperative period.

S M Cohn1, K A Cohn, M J Rafferty, A H Smith, L C Degutis, S F Kowalsky, A Shah.   

Abstract

We studied the enteric absorption of ciprofloxacin immediately following major abdominal surgery to determine if this drug could replace parenteral agents. Nine critically ill subjects received ciprofloxacin, 750 mg, every 12 h for 48 h via nasogastric tube. Drug concentrations were measured after the first and fourth doses. There was insignificant absorption after the initial dose, Cmax = 0.6 +/- 0.6 (mg/L) and AUC0-12 = 3.5 +/- 3.2 (mg.h/L). Unfortunately, serum ciprofloxacin concentrations were also minimally detectable in three of nine subjects after the fourth dose. Enteric absorption of ciprofloxacin, therefore, was erratic and unpredictable in critically ill patients following major abdominal surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591948     DOI: 10.1093/jac/36.4.717

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.

Authors:  S de Marie; M F VandenBergh; S L Buijk; H A Bruining; A van Vliet; J A Kluytmans; J W Mouton
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 2.  Cost effectiveness of quinolones in hospitals and the community.

Authors:  P Davey
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 3.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 4.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.